BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 15593188)

  • 1. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
    Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
    Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
    Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
    Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital ulcers: overt vascular disease in systemic sclerosis.
    Steen V; Denton CP; Pope JE; Matucci-Cerinic M
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
    Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
    Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
    J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers.
    Richetta AG; Mattozzi C; Maiani E; D'Epiro S; Cimillio M; Carboni V; Giancristoforo S; Calvieri S
    Clin Ter; 2008; 159(5):317-9. PubMed ID: 18998033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan for digital ulcers in patients with systemic sclerosis.
    Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
    J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital ulcers and outcomes assessment in scleroderma.
    Matucci-Cerinic M; Seibold JR
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v46-7. PubMed ID: 18784143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
    Launay D; Diot E; Pasquier E; Mouthon L; Boullanger N; Fain O; Jego P; Carpentier P; Hatron PY; Hachulla E
    Presse Med; 2006 Apr; 35(4 Pt 1):587-92. PubMed ID: 16614599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
    Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
    JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan.
    Zelenietz C; Pope J
    Ann Rheum Dis; 2010 Nov; 69(11):2055-6. PubMed ID: 20959328
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
    Dhillon S
    Drugs; 2009 Oct; 69(14):2005-24. PubMed ID: 19747014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.